Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has issued an announcement.
IRLAB Therapeutics announced that CEO Kristina Torfgård will present at the Redeye Theme: Neurology event in Stockholm, providing an opportunity to engage with Swedish and international investors. This presentation could enhance IRLAB’s network and potentially lead to new collaborations, reinforcing its position in the neurology sector.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing novel treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company is advancing a portfolio of treatments for various stages of Parkinson’s, including Mesdopetam for levodopa-induced dyskinesias and Pirepemat for reducing fall frequency. IRLAB employs a proprietary systems biology-based research platform and is listed on Nasdaq Stockholm.
Average Trading Volume: 210,838
Technical Sentiment Signal: Sell
Current Market Cap: SEK248M
See more data about IRLAB.A stock on TipRanks’ Stock Analysis page.